Answers are grounded in this paper and cite their sources.
Galacto-oligosaccharides (GOS) may modulate intestinal inflammation. We evaluated dietary GOS in male and female zebrafish challenged with 2,4,6-trinitrobenzenesulfonic acid (TNBS). Enzymatically produced GOS was characterized, and network pharmacology identified candidate targets. Zebrafish received diets containing 0.4% GOS or inulin for 35 days before intraperitoneal TNBS administration (200 mM in 25% ethanol; 1 μL/0.1 g body weight). Survival was monitored for 96 h in four groups. Histology included an additional GOS-only group sampled at the same endpoint. Distal intestinal cytokine mRNA expression and histology were assessed using RT-qPCR, hematoxylin and eosin staining, and Alcian blue-periodic acid-Schiff (AB-PAS) staining. Continuous outcomes were analyzed by two-way ANOVA. GOS purity was 96.62%. After TNBS challenge, GOS was associated with lower pro-inflammatory cytokine mRNA expression and histological injury scores and a larger AB-PAS-positive area. Compared with TNBS alone, IL-10 expression was lower with GOS in females but was not significantly increased in males. Histological injury scores showed a sex × group interaction (p = 0.0497). Overall survival differences did not establish a GOS-specific survival benefit. Dietary GOS may attenuate TNBS-associated intestinal inflammation and histological injury in a preventive setting. GOS-specific sex-dependent efficacy and the predicted molecular targets remain unconfirmed.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: